Treating paediatric convergence

Article

Office-based vergence/accommodative therapy with home reinforcement (OBVAT) is the most effective method of treating symptomatic convergence insufficiency when compared with any other home- or office-based placebo or therapy, according to study results published in the October issue of the Archives of Ophthalmology.

Office-based vergence/accommodative therapy with home reinforcement (OBVAT) is the most effective method of treating symptomatic convergence insufficiency when compared with any other home- or office-based placebo or therapy, according to study results published in the October issue of the Archives of Ophthalmology.

Stacey Coulter, OD of Nova Southeastern University, Florida, US and colleagues conducted the 12-week Convergence Insufficiency Treatment Trial (CITT) in subjects aged 9–17 years (n=221), who were randomized to receive OBVAT, home-based pencil push-ups (HBPP), office-based placebo therapy with home reinforcement (OBPT) or home-based computer vergence/accommodative therapy and pencil push-ups (HBCVAT+) treatment.

At 12 weeks, the Covergence Insufficiency Symptom Scores for the OBVAT, HBPP, OBPT and HBCVAT+ therapies were 15.1, 24.7, 21.9 and 21.3, respectively. The success or improvement rates for each of these therapies were 73%, 43%, 35% and 33%, respectively.

Based on these results, Dr Coulter's team concluded that OBVAT is the best method of treating convergence insufficiency.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.